Suppr超能文献

在伴有凝胶支架植入的兔滤过性手术模型中使用新型结膜下持续释放丝裂霉素 C 制剂。

Using a Novel, Subconjunctival, Sustained-Release Mitomycin C Formulation in a Rabbit Model of Filtration Surgery with Gel Stent Implantation.

机构信息

Allergan, an AbbVie company, Irvine, California, USA.

Retina Foundation of the Southwest, Dallas, Texas, USA.

出版信息

J Ocul Pharmacol Ther. 2024 Jun;40(5):297-308. doi: 10.1089/jop.2023.0100. Epub 2024 May 2.

Abstract

To investigate gel stent implantation with and without intraoperative sustained-release mitomycin C (MMC SR) in a rabbit model for gel stent implantation, and to examine aqueous humor outflow (AHO) postimplantation. Four groups of rabbits were included. Group 1 was untreated (control). Groups 2, 3, and 4 received the gel stent without MMC, with MMC solution (subconjunctival injection), and with MMC SR (subconjunctival injection), respectively. Intraocular pressure (IOP) and AHO were assessed via tonometry and indocyanine green-based angiography, respectively. The main efficacy measure was change in IOP from baseline. Following gel stent implantation, Groups 2, 3, and 4 maintained ≥20% IOP reduction (response) for a median duration of 1 week, 6.5 weeks, and 30 weeks, respectively. Angiography showed normal aqueous humor drainage (Group 1) beginning at the perilimbal trabecular plexus and continuing posteriorly to episcleral outflow vessels. Following implantation, drainage occurred preferentially and directly into the subconjunctival bleb. Gel stent implantation with MMC SR was most effective in achieving sustained, long-term IOP reduction in the rabbit model, compared with implantation with or without MMC solution. Bleb presence and the postimplantation aqueous angiography results indicated redirection of the AHO to the subconjunctival vasculature and presumed lymphatics, suggesting efficient glaucoma filtration to lower IOP in this model. This rabbit model and aqueous angiography may help refine understanding of the mechanism of action of minimally invasive glaucoma surgeries and ultimately translate to improved surgical devices and procedures for patients with glaucoma.

摘要

为了研究凝胶支架植入术中应用和不应用术中持续释放丝裂霉素 C(MMC SR)在兔模型中的效果,并检查植入后房水流出(AHO)的情况。本研究纳入了四组兔子。第 1 组未治疗(对照组)。第 2、3 和 4 组分别接受了无 MMC 的凝胶支架、MMC 溶液(结膜下注射)和 MMC SR(结膜下注射)。通过眼压计评估眼内压(IOP),通过吲哚菁绿血管造影评估房水流出。主要疗效指标是从基线开始 IOP 的变化。在凝胶支架植入后,第 2、3 和 4 组分别维持了≥20%的 IOP 降低(反应),中位持续时间分别为 1 周、6.5 周和 30 周。血管造影显示正常房水引流(第 1 组),从角膜缘小梁丛开始,向后延伸至巩膜外流出血管。植入后,房水引流优先且直接进入结膜下囊泡。与单独应用 MMC 溶液或不应用 MMC 相比,在兔模型中,MMC SR 凝胶支架植入在实现持续、长期的 IOP 降低方面最有效。囊泡的存在和植入后的房水血管造影结果表明,AHO 被重新引导到结膜下血管和假定的淋巴管,表明在该模型中,有效的青光眼滤过可降低 IOP。这种兔模型和房水血管造影可能有助于深入了解微创青光眼手术的作用机制,并最终为青光眼患者带来改进的手术设备和手术程序。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/038d/11296147/208ec6a38a45/jop.2023.0100_figure1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验